Crossmark

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection

Crossref DOI link: https://doi.org/10.1186/s12974-019-1404-9

Published Online: 2019-01-24

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hermansson, Linn

Yilmaz, Aylin https://orcid.org/0000-0001-7612-5828
Axelsson, Markus

Blennow, Kaj

Fuchs, Dietmar

Hagberg, Lars

Lycke, Jan

Zetterberg, Henrik

Gisslén, Magnus
Funding

Funding for this research was provided by:

Swedish State support for Clinical Research (ALFGBG-717531, ALFGBG-715986, and ALFGBG-720931)

National Institutes of Health (R01 NS094067)
License Information

Text and Data Mining valid from 2019-01-24

Version of Record valid from 2019-01-24
More Information

Article History

Received: 26 September 2018

Accepted: 9 January 2019

First Online: 24 January 2019

Ethics approval and consent to participate

: The study was approved by the Regional Ethics Review Board in Gothenburg, Sweden (Ö588-01) and was performed in accordance with the Helsinki Declaration. All participants gave their informed consent.

: Not applicable

: HZ has served on scientific advisory boards for Eli Lilly, Roche Diagnostics, and Wave; he has received travel grants from Teva; and he is also a co-founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg.KB has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics. He is also a co-founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below